Core Insights - The partnership between Rapport Therapeutics and Tenacia Biotechnology aims to leverage Tenacia's expertise in CNS drug development to accelerate the global development of RAP-219, a potential first-in-class therapy for neurological disorders [1][4] Financial Terms - Rapport will receive an upfront cash payment of $20 million, with potential additional payments of up to $308 million in development and commercialization milestones, along with tiered royalties on net sales in Greater China [3][4] Product Development - RAP-219 is being developed for multiple indications, including focal onset seizures and bipolar mania, and has shown promising results in a Phase 2a trial, demonstrating significant reductions in seizure episodes [2][6] - Two global registrational trials for RAP-219 will be conducted, with a Phase 3 program expected to start in Q2 2026, expanding its clinical trial sites in China under Tenacia's leadership [2][3] Company Profiles - Rapport Therapeutics focuses on developing small molecule precision medicines for neurological and psychiatric disorders, with a strong emphasis on epilepsy and bipolar disorder [7] - Tenacia Biotechnology, founded in 2022, aims to develop innovative therapeutics for underserved neurological disorders and is backed by Bain Capital, enhancing its capabilities in drug development [8]
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China